Medical Management of Persistent and Recurrent Cushing Disease

Neurosurgery Clinics of North America

Volumn 23, Issue 4, 2012, Pages 653-668

  Fleseriu, Maria ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adrenal steroidogenesis inhibitors; Cushing disease; Failed transphenoidal surgery; Glucocorticoid receptor antagonist; Mifepristone; Pasireotide; Recurrent Cushing disease; Somatostatin receptor ligands

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLUTETHIMIDE; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CYPROHEPTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOMIDATE; GEFITINIB; GLUCOCORTICOID; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MITOTANE; OCTREOTIDE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM; RETINOIC ACID; RETINOIC ACID RECEPTOR; SEROTONIN ANTAGONIST; SOMATOSTATIN RECEPTOR; SPIRONOLACTONE; TRILOSTANE; UNINDEXED DRUG; VALPROIC ACID;

ACNE; ADRENAL INSUFFICIENCY; ANAPHYLAXIS; ARTHRALGIA; BLURRED VISION; CONFUSION; COUGHING; CUSHING DISEASE; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; ENDOMETRIAL DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HICCUP; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INJECTION SITE PAIN; KIDNEY FAILURE; LETHARGY; LIVER DISEASE; LIVER DYSCRASIA; LIVER TOXICITY; MONOTHERAPY; MORBIDITY; MYOCLONUS; NAUSEA; NONHUMAN; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STRUCTURE ANALYSIS; SURGICAL MORTALITY; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

HUMANS; NEOPLASM RECURRENCE, LOCAL; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84867124316     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.06.012     Document Type: Review

References (114)

1. Lindholm J., Juul S., Jorgensen J.O., et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001, 86(1):117-123.
2. Arnardottir S., Sigurjonsdottir H.A. The incidence and prevalence of Cushing's disease may be higher than previously thought: results from a retrospective study in Iceland 1955 through 2009. Clin Endocrinol (Oxf) 2011, 74(6):792-793.
3. Bolland M.J., Holdaway I.M., Berkeley J.E., et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf) 2011, 75(4):436-442.
4. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege. J Clin Endocrinol Metab 2006, 91(12):4769-4775.
5. Fernandez A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010, 72(3):377-382.
6. Blevins L.S., Sanai N., Kunwar S., et al. An approach to the management of patients with residual Cushing's disease. J Neurooncol 2009, 94(3):313-319.
7. Catargi B., Rigalleau V., Poussin A., et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003, 88(12):5808-5813.
8. Chiodini I., Mascia M.L., Muscarella S., et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med 2007, 147(8):541-548.
9. Leibowitz G., Tsur A., Chayen S.D., et al. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996, 44(6):717-722.
10. Arnaldi G., Angeli A., Atkinson A.B., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88(12):5593-5602.
11. Barahona M.J., Sucunza N., Resmini E., et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 2009, 94(9):3365-3371.
12. De Leo M., Pivonello R., Auriemma R.S., et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology 2010, 92(Suppl 1):50-54.
13. Toja P.M., Branzi G., Ciambellotti F., et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol (Oxf) 2011, 76(3):332-338.
14. Valassi E., Biller B.M., Swearingen B., et al. Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J Clin Endocrinol Metab 2010, 95(2):601-610.
15. Pivonello R., De Martino M.C., De Leo M., et al. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol 2007, 51(8):1381-1391.
16. Valassi E., Biller B.M., Klibanski A., et al. Adipokines and cardiovascular risk in Cushing's syndrome. Neuroendocrinology 2011, 95(3):187-206.
17. Clayton R.N., Raskauskiene D., Reulen R.C., et al. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011, 96(3):632-642.
18. Sughrue M.E., Chang E.F., Gabriel R.A., et al. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 2011, 14(3):276-283.
19. Biller B.M., Grossman A.B., Stewart P.M., et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008, 93(7):2454-2462.
20. Chandler W.F., Schteingart D.E. Controversies in the management of Cushing's disease. Clin Neurosurg 1986, 33:553-562.
21. Chee G.H., Mathias D.B., James R.A., et al. Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome?. Clin Endocrinol (Oxf) 2001, 54(5):617-626.
22. Aghi M.K. Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 2008, 4(10):560-568.
23. Tritos N.A., Biller B.M., Swearingen B. Management of Cushing disease. Nat Rev Endocrinol 2011, 7(5):279-289.
24. Czepielewski M.A., Rollin G.A., Casagrande A., et al. Criteria of cure and remission in Cushing's disease: an update. Arq Bras Endocrinol Metabol 2007, 51(8):1362-1372.
25. Fleseriu M., Loriaux D.L., Ludlam W.H. Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. Curr Opin Endocrinol Diabetes Obes 2007, 14(4):323-328.
26. Utz A.L., Swearingen B., Biller B.M. Pituitary surgery and postoperative management in Cushing's disease. Endocrinol Metab Clin North Am 2005, 34(2):459-478. xi.
27. Atkinson A.B., Kennedy A., Wiggam M.I., et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005, 63(5):549-559.
28. Patil C.G., Prevedello D.M., Lad S.P., et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008, 93(2):358-362.
29. Hoybye C., Grenback E., Thoren M., et al. Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases. J Neurosurg 2004, 100(4):634-638.
30. Miller J.W., Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 1993, 14(4):443-458.
31. Pivonello R., De Martino M.C., De Leo M., et al. Cushing's syndrome. Endocrinol Metab Clin North Am 2008, 37(1):135-149. ix.
32. Baudry C, Coste J, Khalil RB, et al. Results of 1, Ortho-1, para'-Dichloro-Diphenyl-Dichloroethane (O, p'DDD) treatment in 76 patients with Cushing disease. Presented at ENDO 2011. Boston, June 4, 2011.
33. Castinetti F., Morange I., Jaquet P., et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008, 158(1):91-99.
34. Colao A, Petersenn S, Newell-Price J, et al. Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, phase III study. Presented at ENDO 2011. Boston, June 4, 2011.
35. Godbout A., Manavela M., Danilowicz K., et al. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 2010, 163(5):709-716.
36. Colao A., Petersenn S., Newell-Price J., et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012, 366(10):914-924.
37. Invitti C., Pecori Giraldi F., de Martin M., et al. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study group of the Italian Society of Endocrinology on the pathophysiology of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1999, 84(2):440-448.
38. Hofmann B.M., Fahlbusch R. Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front Horm Res 2006, 34:158-184.
39. Ram Z., Nieman L.K., Cutler G.B., et al. Early repeat surgery for persistent Cushing's disease. J Neurosurg 1994, 80(1):37-45.
40. Friedman R.B., Oldfield E.H., Nieman L.K., et al. Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg 1989, 71(4):520-527.
41. Losa M., Picozzi P., Redaelli M.G., et al. Pituitary radiotherapy for Cushing's disease. Neuroendocrinology 2010, 92(Suppl 1):107-110.
42. Young W.F., Thompson G.B. Laparoscopic adrenalectomy for patients who have Cushing's syndrome. Endocrinol Metab Clin North Am 2005, 34(2):489-499.
43. Assie G., Bahurel H., Coste J., et al. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab 2007, 92(1):172-179.
44. Nieman L.K. Medical therapy of Cushing's disease. Pituitary 2002, 5(2):77-82.
45. Colao A., Pivonello R., Tripodi F.S., et al. Failure of long-term therapy with sodium valproate in Cushing's disease. J Endocrinol Invest 1997, 20(7):387-392.
46. Pivonello R., Ferone D., de Herder W.W., et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004, 89(5):2452-2462.
47. Hofland L.J., van der Hoek J., Feelders R., et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005, 152(4):645-654.
48. Gatto F., Hofland L.J. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocrine 2011, 18(6):R233-R251.
49. Suda T., Tozawa F., Mouri T., et al. Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease. J Clin Endocrinol Metab 1983, 56(6):1094-1099.
50. Tanakol R., Alagol F., Azizlerli H., et al. Cyproheptadine treatment in Cushing's disease. J Endocrinol Invest 1996, 19(4):242-247.
51. Koppeschaar H.P., Croughs R.J., Thijssen J.H., et al. Response to neurotransmitter modulating drugs in patients with Cushing's disease. Clin Endocrinol (Oxf) 1986, 25(6):661-667.
52. Heaney A.P. PPAR-gamma in Cushing's disease. Pituitary 2004, 7(4):265-269.
53. Ambrosi B., Dall'Asta C., Cannavo S., et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004, 151(2):173-178.
54. Pecori Giraldi F., Scaroni C., Arvat E., et al. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 2006, 64(2):219-224.
55. Mannelli M., Cantini G., Poli G., et al. Role of the PPAR-gamma system in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology 2010, 92(Suppl 1):23-27.
56. Mercado-Asis L.B., Yasuda K., Murayama M., et al. Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol Jpn 1992, 39(4):385-395.
57. Lamberts S.W., Birkenhager J.C. Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet 1976, 2(7989):811.
58. Bevan J.S., Webster J., Burke C.W., et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992, 13(2):220-240.
59. Whitehead H.M., Beacom R., Sheridan B., et al. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy. Clin Endocrinol (Oxf) 1990, 32(2):193-201.
60. Casulari L.A., Naves L.A., Mello P.A., et al. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004, 62(6):300-305.
61. Godbout A, Manavela M, Danilowicz K, et al. Long-term therapy with cabergoline in Cushing's disease [abstract: P2-130]. Presented at the Endocrine Society's 90th meeting. San Francisco, 2008.
62. Vilar L., Naves L.A., Azevedo M.F., et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 2010, 13(2):123-129.
63. Pivonello R., De Martino M.C., Cappabianca P., et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009, 94(1):223-230.
64. Lamberts S.W., Zuyderwijk J., den Holder F., et al. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 1989, 50(1):44-50.
65. Stalla G.K., Brockmeier S.J., Renner U., et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 1994, 130(2):125-131.
66. van der Hoek J., Waaijers M., van Koetsveld P.M., et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005, 289(2):E278-E287.
67. Batista D.L., Zhang X., Gejman R., et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006, 91(11):4482-4488.
68. Boscaro M., Ludlam W.H., Atkinson B., et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009, 94(1):115-122.
69. Petersenn S., Schopohl J., Barkan A., et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010, 95(6):2781-2789.
70. Murray R.D., Kim K., Ren S.G., et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004, 89(6):3027-3032.
71. Ben-Shlomo A., Schmid H., Wawrowsky K., et al. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 2009, 94(11):4342-4350.
72. Ben-Shlomo A., Wawrowsky K.A., Proekt I., et al. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 2005, 280(25):24011-24021.
73. The European Medicines Agency. Signifor. Available at: Accessed January 23, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002052/smops/Positive/human_smop_000326.jsp&mid=WC0b01ac058001d127&jsenabled=true.
74. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001, 1(3):181-193.
75. Labeur M., Paez-Pereda M., Arzt E., et al. Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas. Rev Endocr Metab Disord 2009, 10(2):103-109.
76. Paez-Pereda M., Kovalovsky D., Hopfner U., et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001, 108(8):1123-1131.
77. Fernando M.A., Heaney A.P. Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 2005, 19(12):3085-3096.
78. Fukuoka H., Cooper O., Ben-Shlomo A., et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 2011, 121(12):4712-4721.
79. Kamenicky P., Droumaguet C., Salenave S., et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011, 96(9):2796-2804.
80. Sonino N., Boscaro M., Paoletta A., et al. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991, 35(4):347-352.
81. Berwaerts J.J., Verhelst J.A., Verhaert G.C., et al. Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole. J Am Geriatr Soc 1998, 46(7):880-884.
82. Chou S.C., Lin J.D. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocr J 2000, 47(4):401-406.
83. Loli P., Berselli M.E., Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab 1986, 63(6):1365-1371.
84. McCance D.R., Hadden D.R., Kennedy L., et al. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1987, 27(5):593-599.
85. Colao A., Di Sarno A., Marzullo P., et al. New medical approaches in pituitary adenomas. Horm Res 2000, 53(Suppl 3):76-87.
86. Sonino N., Boscaro M., Merola G., et al. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab 1985, 61(4):718-722.
87. Tabarin A., Navarranne A., Guerin J., et al. Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1991, 34(1):63-69.
88. Boscaro M., Sonino N., Rampazzo A., et al. Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin Endocrinol (Oxf) 1987, 27(4):461-467.
89. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 1986, 7(4):409-420.
90. AHFS Consumer Medication Information. Ketoconazole. Available at: Accessed January 23, 2012. http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON028267.
91. Schteingart D.E., Tsao H.S., Taylor C.I., et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980, 92(5):613-619.
92. Luton J.P., Mahoudeau J.A., Bouchard P., et al. Treatment of Cushing's disease by O, p'DDD. Survey of 62 cases. N Engl J Med 1979, 300(9):459-464.
93. Leiba S., Weinstein R., Shindel B., et al. The protracted effect of o, p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989, 50(1):49-53.
94. Schteingart D.E. Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 2009, 14(4):661-671.
95. Verhelst J.A., Trainer P.J., Howlett T.A., et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991, 35(2):169-178.
96. Karaca Z., Tanriverdi F., Unluhizarci K., et al. Pregnancy and pituitary disorders. Eur J Endocrinol 2010, 162(3):453-475.
97. Engelhardt D., Weber M.M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994, 49(4-6):261-267.
98. Heyn J., Geiger C., Hinske C.L., et al. Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate. Pituitary 2012, 15(2):117-125.
99. Schulte H.M., Benker G., Reinwein D., et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990, 70(5):1426-1430.
100. Paris A., Philipp M., Tonner P.H., et al. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 2003, 99(4):889-895.
101. Herrmann B.L., Mitchell A., Saller B., et al. Dtsch Med Wochenschr 2001, 126(9):232-234. [in German].
102. Mettauer N., Brierley J. A novel use of etomidate for intentional adrenal suppression to control severe hypercortisolemia in childhood. Pediatr Crit Care Med 2009, 10(3):e37-e40.
103. Allolio B., Schulte H.M., Kaulen D., et al. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr 1988, 66(8):361-364.
104. Dabbagh A., Sa'adat N., Heidari Z. Etomidate infusion in the critical care setting for suppressing the acute phase of Cushing's syndrome. Anesth Analg 2009, 108(1):238-239.
105. Trainer P.J., Eastment C., Grossman A.B., et al. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin Endocrinol (Oxf) 1993, 39(4):441-443.
106. Johanssen S., Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007, 157(5):561-569.
107. Castinetti F., Fassnacht M., Johanssen S., et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009, 160(6):1003-1010.
108. Chu J.W., Matthias D.F., Belanoff J., et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001, 86(8):3568-3573.
109. Nieman L.K., Chrousos G.P., Kellner C., et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985, 61(3):536-540.
110. Fleseriu M, Biller B, Findling J, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with refractory Cushing syndrome: results from the study of the efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome (SEISMIC). Presented at ENDO 2011. Boston, June 4, 2011.
111. Fleseriu M., Biller B.M., Findling J.W., et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012, 97(6):2039-2049.
112. Vignati F., Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J Clin Endocrinol Metab 1996, 81(8):2885-2890.
113. Rocheville M., Lange D.C., Kumar U., et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288(5463):154-157.
114. Feelders R.A., de Bruin C., Pereira A.M., et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010, 362(19):1846-1848.